Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia

Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, USA.
Blood (Impact Factor: 10.43). 03/2005; 105(4):1797-802. DOI: 10.1182/blood-2004-08-3375
Source: PubMed

ABSTRACT The iron-regulatory hormone hepcidin has been proposed as the mediator of anemia of inflammation (AI). We examined the acute and chronic effects of hepcidin in the mouse. Injections of human hepcidin (50 microg/mouse), but not of its diluent, induced hypoferremia within 4 hours. To examine the chronic effects of hepcidin, we implanted either tumor xenografts engineered to overexpress human hepcidin or control tumor xenografts into nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mice. Despite abundant dietary iron, mice with hepcidin-producing tumors developed more severe anemia, lower serum iron, and increased hepatic iron compared with mice with control tumors. Hepcidin contributes to AI by shunting iron away from erythropoiesis and sequestering it in the liver, predominantly in hepatocytes.

Download full-text


Available from: Ole E Sørensen, Jul 05, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this observational study was to assess the prevalence of iron-restricted erythropoiesis (IRE) in a population of elderly hospitalized anemic patients. Prevalence of IRE was found to be 41% and the most common clinical diagno-ses in such patients were hematologic malignancies and solid tumors. Comparison between patients with IRE and non-IRE patients revealed that mean corpuscular volume, mean corpuscular hemoglobin, iron, and transferrin saturation were significantly lower in the IRE group, whereas no significant difference was found for Hb, transferrin, or ferritin. There was a more pronounced inflammatory response in the IRE group demonstrated by a higher C-reactive protein level.
    Open Journal of Blood Diseases 01/2012; 02(02). DOI:10.4236/ojbd.2012.22006
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: During the past decade, intravenous iron supplementation to ESA (erythropoiesis-stimulating agent) therapy has emerged as an option to augment hemoglobin response in anemic cancer patients. In this paper, the results of seven published randomized clinical trials assessing the role of iron supplementation to ESA therapy in the hematology/oncology setting will be discussed. The pathogenetic mechanisms behind functional iron deficiency, a major reason for ESA hyporesponsiveness in cancer, will also be described.
    10/2011; 2011:108397. DOI:10.5402/2011/108397
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Summary Hepcidin is an important and recently discovered regulator of iron homeostasis. There is strong evidence in support of an important role for hepcidin dysregulation in the pathogenesis of iron overload disorders, and possibly in the aetiology of the anaemia of chronic disease. Further research is needed into the physiology of hepcidin to elucidate the relative contributions of the liver and kidney to its production and metabolism. The study of the differential roles of prohepcidin and its metabolites as well as the significance of their serum and urine levels will enhance our understanding of their role in iron metabolism.
    Clinical & Laboratory Haematology 05/2006; 28(2):75-83. DOI:10.1111/j.1365-2257.2006.00768.x · 1.30 Impact Factor